Altogether, these findings establish DNA-PKcs inhibition as a promising strategy to overcome DDP resistance in NSCLC through selective disruption of NHEJ-mediated DNA repair, abrogation of NF-κB-driven stemness programs, and potentiation of apoptosis without HR pathway compensation. This evidence concerns the gene PRKDC and non-small cell lung carcinoma.